Benjamin Bouchacourt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Bouchacourt has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Boris Calmels
Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France
6 shared publications - Didier Blaise
Departement D’Hematologie, Programme de Transplantation et de Therapie Cellulaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
6 shared publications Samia Harbi
Hematology Department, Institut Paoli-Calmettes, Marseille, France
6 shared publications- Christian Chabannon
Institut Paoli-Calmettes, Inserm CBT-1409 & Aix-Marseille Université, Marseille, France
5 shared publications Faezeh Legrand
Department of Hematology, Institut Paoli Calmettes, Marseille, France
5 shared publications- Raynier Devillier
Transplantation and cellular immunotherapy program, Department of Hematology, Institut Paoli Calmettes, Management Sport Cancer Lab, Aix Marseille Univ, Marseille, France
5 shared publications
Latest Publications
- 27 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1188-1195
Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients
Allogeneic stem-cell transplantation (allo-SCT) is met with increased toxicity and relapse in elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The nonmyeloablative conditioning (NMAC) regimen combining 2GyTBI, fludarabine, and cyclophosphamide (FluCyTBI) with post-transplant cyclophosphamide (PTCy) has been described as well adapted to AML/MDS patients aged ≥70yo in the haplo-identical setting. PTCy has then been implemented as basis for GVHD prophylaxis in allo-SCT with unrelated donors (UD). We here report our experience with a single FluCyTBI+PTCy platform for both haplo and UD allo-SCT in older AML or high-risk MDS patients. We retrospectively analyzed 203 patients transplanted at our center between 2015 and 2024. Median age at transplant was 69. Donors were haplo, mismatched UD, and matched UD in 64%, 18% and 18% of patients, respectively. Day+100 grade III-IV acute GVHD (aGVHD) and 3-y moderate/severe chronic GVHD (cGVHD) rates were 8% and 18%. Donor age ≥35yo was predictive of increased aGVHD III-IV and female-to-male sex-mismatch was associated with increased moderate/severe cGVHD. 3-y NRM rate was 15%. 3-y OS was 62%, with only monosomal karyotype predicting worse survival. FluCyTBI+PTCy is safe and produces promising outcomes in both haplo and UD settings. Beyond HLA-matching, non-HLA donor-related factors constitute critical determinants of patient outcome.
- 27 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1188-1195
Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients
Allogeneic stem-cell transplantation (allo-SCT) is met with increased toxicity and relapse in elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The nonmyeloablative conditioning (NMAC) regimen combining 2GyTBI, fludarabine, and cyclophosphamide (FluCyTBI) with post-transplant cyclophosphamide (PTCy) has been described as well adapted to AML/MDS patients aged ≥70yo in the haplo-identical setting. PTCy has then been implemented as basis for GVHD prophylaxis in allo-SCT with unrelated donors (UD). We here report our experience with a single FluCyTBI+PTCy platform for both haplo and UD allo-SCT in older AML or high-risk MDS patients. We retrospectively analyzed 203 patients transplanted at our center between 2015 and 2024. Median age at transplant was 69. Donors were haplo, mismatched UD, and matched UD in 64%, 18% and 18% of patients, respectively. Day+100 grade III-IV acute GVHD (aGVHD) and 3-y moderate/severe chronic GVHD (cGVHD) rates were 8% and 18%. Donor age ≥35yo was predictive of increased aGVHD III-IV and female-to-male sex-mismatch was associated with increased moderate/severe cGVHD. 3-y NRM rate was 15%. 3-y OS was 62%, with only monosomal karyotype predicting worse survival. FluCyTBI+PTCy is safe and produces promising outcomes in both haplo and UD settings. Beyond HLA-matching, non-HLA donor-related factors constitute critical determinants of patient outcome.
- 14 March 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (7) , 918-927
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy. To reduce the risk of engraftment failure, a sequential two courses pharmacological pre-transplant immune suppression (PTIS) phase was added prior to the conditioning regimen. All patients engrafted successfully. The procedure was well tolerated. None of the patients developed acute GVHD, whereas one developed moderate chronic GVHD. After a median follow-up of 5 years (range, 2.2–9), all patients are free of pain with excellent quality of life. Our report shows that Haplo-SCT after a RT-MAC regimen is feasible and safe with stable long-term engraftment and excellent disease control. The risk of graft failure can be abrogated by adding a PTIS phase prior to initiating the conditioning regimen.
- 14 March 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (7) , 918-927
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy. To reduce the risk of engraftment failure, a sequential two courses pharmacological pre-transplant immune suppression (PTIS) phase was added prior to the conditioning regimen. All patients engrafted successfully. The procedure was well tolerated. None of the patients developed acute GVHD, whereas one developed moderate chronic GVHD. After a median follow-up of 5 years (range, 2.2–9), all patients are free of pain with excellent quality of life. Our report shows that Haplo-SCT after a RT-MAC regimen is feasible and safe with stable long-term engraftment and excellent disease control. The risk of graft failure can be abrogated by adding a PTIS phase prior to initiating the conditioning regimen.
- 3 November 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (1) , 101-106
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients aged 70 years and over with AML and MDS. Thus the benefit of transplantation in this population is still debated. Here we report our single center experience of peripheral blood Haplo-SCT with NMAC and post-transplantation cyclophosphamide in AML and MDS patients aged 70 years and over. We analyzed 50 patients (27 AML, 23 MDS) with a median age of 72 years (70–77), 12/50 (24%) with active disease at Haplo-SCT. Cumulative incidence of grade 3–4 acute and moderate or severe chronic GVHD were 6% and 25%, respectively. Non-relapse mortality (NRM) at day +100 was 0%. NRM, relapse, PFS and OS at 3 years were 16%, 18%, 66%, and 69%, respectively. Among patients who were disease free at 2 years post Haplo-SCT, 88% are living without immunosuppressive treatment. Peripheral blood Haplo-SCT is feasible in selected AML/MDS patients over 70 years, without any early NRM. It produces long-term disease control and survival. Thus, age by itself should not be considered as a formal barrier to Haplo-SCT.
- 3 November 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (1) , 101-106
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients aged 70 years and over with AML and MDS. Thus the benefit of transplantation in this population is still debated. Here we report our single center experience of peripheral blood Haplo-SCT with NMAC and post-transplantation cyclophosphamide in AML and MDS patients aged 70 years and over. We analyzed 50 patients (27 AML, 23 MDS) with a median age of 72 years (70–77), 12/50 (24%) with active disease at Haplo-SCT. Cumulative incidence of grade 3–4 acute and moderate or severe chronic GVHD were 6% and 25%, respectively. Non-relapse mortality (NRM) at day +100 was 0%. NRM, relapse, PFS and OS at 3 years were 16%, 18%, 66%, and 69%, respectively. Among patients who were disease free at 2 years post Haplo-SCT, 88% are living without immunosuppressive treatment. Peripheral blood Haplo-SCT is feasible in selected AML/MDS patients over 70 years, without any early NRM. It produces long-term disease control and survival. Thus, age by itself should not be considered as a formal barrier to Haplo-SCT.
- 9 August 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (11) , 1179-1181
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation
- 9 August 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (11) , 1179-1181
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 12811-12812
Prep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation
Introduction: Donor recruitment in allogeneic hematopoietic stem cell transplantation (HSCT) is a multi-step process involving several stakeholders: patients, d
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 12811-12812
Open AccessPrep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation
Introduction: Donor recruitment in allogeneic hematopoietic stem cell transplantation (HSCT) is a multi-step process involving several stakeholders: patients, d
- Open Access
- 27 September 2022
- Published by Springer Nature in Research Square
Post-transplant cyclophosphamide versus antithymocyte globulin as GVHD prophylaxis for 10/10 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.
After T-cell replete haploidentical stem cell transplantation, GVHD prophylaxis with post-transplant cyclophosphamide (PT-Cy) is now evaluated in unrelated donor (UD) transplants, where antithymocyte globulin (ATG) remains standard. We report the outcome of patients transplanted from HLA-10/10 matched unrelated donor (MUD) treated with PT-Cy (n=30), in comparison with a historical cohort treated with ATG (n=64). In the PT-Cy group, we observed lower 2-4 acute GVHD (23% vs. 45%, p=0.014), lower chronic GVHD (all grades: 13% vs 33%, p=0.029; moderate to severe: 10% vs. 27%, p=0.039) but no difference in the relapse (20% vs. 11%, p=0.628), non-relapse mortality (3% vs 11%, p=0.169), progression free survival (77% vs 78%, p=0.638) and overall survival (87% vs 83%, p=0.602). Neutrophil (19 vs 17 days, p=0.049) and platelet (26 vs 10 days, p<0.001) recovery was significantly delayed in the PT-Cy group. Then, we followed the GVHD and the immunosuppressive treatments (IST) prevalence in disease free patients as marker of quality of life. At 6 months, 5% and 36% in the PT-Cy group were living with GVHD and IST, versus 26% (p=0.030) and 64% (p=0.049). We conclude that PT-Cy is an effective GVHD prophylaxis in 10/10-HLA MUD allo-SCT, representing a valuable alternative to ATG.
- 27 September 2022
- Published by Springer Nature in Research Square
Open AccessPost-transplant cyclophosphamide versus antithymocyte globulin as GVHD prophylaxis for 10/10 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.
After T-cell replete haploidentical stem cell transplantation, GVHD prophylaxis with post-transplant cyclophosphamide (PT-Cy) is now evaluated in unrelated donor (UD) transplants, where antithymocyte globulin (ATG) remains standard. We report the outcome of patients transplanted from HLA-10/10 matched unrelated donor (MUD) treated with PT-Cy (n=30), in comparison with a historical cohort treated with ATG (n=64). In the PT-Cy group, we observed lower 2-4 acute GVHD (23% vs. 45%, p=0.014), lower chronic GVHD (all grades: 13% vs 33%, p=0.029; moderate to severe: 10% vs. 27%, p=0.039) but no difference in the relapse (20% vs. 11%, p=0.628), non-relapse mortality (3% vs 11%, p=0.169), progression free survival (77% vs 78%, p=0.638) and overall survival (87% vs 83%, p=0.602). Neutrophil (19 vs 17 days, p=0.049) and platelet (26 vs 10 days, p<0.001) recovery was significantly delayed in the PT-Cy group. Then, we followed the GVHD and the immunosuppressive treatments (IST) prevalence in disease free patients as marker of quality of life. At 6 months, 5% and 36% in the PT-Cy group were living with GVHD and IST, versus 26% (p=0.030) and 64% (p=0.049). We conclude that PT-Cy is an effective GVHD prophylaxis in 10/10-HLA MUD allo-SCT, representing a valuable alternative to ATG.
- 22 February 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (4) , 773-780
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.
- 22 February 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (4) , 773-780
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.